Neurological and psychiatric presentations associated with human monkeypox virus infection: a systematic review and meta-analysis

James B Badenoch, Isabella Conti, Emma R Rengasamy, Cameron J Watson, Matthew Butler, Zain Hussain, Alasdair G Rooney, Michael S Zandi, Glyn Lewis, Anthony S David, Catherine F Houlihan, Ava Easton, Benedict D Michael, Krutika Kuppalli, Timothy R Nicholson, Thomas A Pollak, Jonathan P Rogers
doi: https://doi.org/10.1101/2022.07.03.22277069

ABSTRACT

Objectives Neuropsychiatric presentations of monkeypox (MPX) infection have not been well characterised, Despite evidence of nervous system involvement associated with two related Orthopoxviruses, in the case of smallpox infection (with the variola virus) and smallpox vaccination (which contains live vaccinia virus). In this systematic review and meta-analysis, we aim to determine the prevalence and describe the spectrum of neurological and psychiatric presentations of MPX.

Design Systematic review and meta-analysis

Data sources MEDLINE, EMBASE, PsycINFO, AMED and pre-print server (MedRxiv) searched up to 31/05/2022

Eligibility criteria for study selection and analysis Any study design of humans infected with MPX that reported neurological or psychiatric presentation. Studies which included more than ten individuals, and symptoms that were reported in a minimum of two separate studies were eligible for meta-analysis

Data synthesis Results were pooled with random-effects meta-analysis to calculate generalised linear mixed models and corresponding 95% confidence intervals for each prevalence outcome.

Heterogeneity was measured with the I2 statistic. All included studies are summarised through a narrative synthesis. Risk of bias was assessed with the Newcastle Ottawa Scale and the Joanna Briggs Institute quality assessment tool.

Results From 1,702 unique studies, we extracted data on 19 eligible studies (1,512 participants, 1,031 with confirmed infection using CDC criteria or PCR testing) most of which were cohort studies and case series with no controlled populations. Study quality was generally moderate. Six clinical features were eligible for meta-analysis, of which the most prevalent were myalgia in 55.5% [95%CI 12.1-91.9%], headache 53.8% [30.6-75.4%], fatigue 36.2% [2.0-94.0%], seizure 2.7% [0.6-10.2%], confusion 2.4% [1.1-5.2%] and encephalitis 2.0% [0.5-8.2%]. Heterogeneity significantly varied across clinical features (I2=0%-98.7%). Other reported presentations not eligible for meta-analysis included sensory-perceptual disturbance (altered vision, dizziness, and photophobia) and psychiatric symptoms (anxiety and depression).

Conclusions There is preliminary evidence for a range of neurological and psychiatric presentations of MPX, ranging from commonly reported and nonspecific neurological symptoms (myalgia and headache) to rarer but more severe neurological complications, such as encephalitis and seizures. There is less evidence regarding the psychiatric sequelae of MPX, and although there are multiple reports of anxiety and depression the prevalence of these symptoms is unknown. MPX-related nervous system presentations may warrant surveillance within the current MPX outbreak, with prospective longitudinal studies evaluating the mid to long-term sequelae of the virus. Robust methods to evaluate the potential causality of MPX with these clinical features are required at an individual and epidemiological level.

Systematic review registration PROSPERO ID 336649

What is already known on this topic

  • Neuropsychiatric symptoms can be highly disabling and have a detrimental effect on quality of life.

  • Neuropsychiatric manifestations of monkeypox virus infection have not been well characterised, however, there is evidence of nervous system involvement with the related smallpox virus and vaccinia vaccine.

What this study adds

  • Preliminary evidence for a range of neurological and psychiatric presentations of monkeypox infection, ranging from commonly reported and nonspecific neurological symptoms (myalgia and headache) to rarer but more severe neurological complications, such as encephalitis and seizures.

  • There is less evidence regarding the psychiatric sequelae of monkeypox infection, and although there are multiple reports of anxiety and depression the prevalence of these symptoms is unknown.

  • This preliminary suspicion that there are monkeypox-related nervous system manifestations may warrant both surveillance within the current monkeypox outbreak and robust methods to evaluate the potential causality.

Introduction

Monkeypox (MPX) is a viral zoonotic disease that belongs to the Orthopoxvirus genus of the Poxviridae family. MPX was first identified in 1958 in monkeys and rodents in a Danish lab, and human cases were first identified in the Democratic Republic of Congo in 19701, 2. MPX virus has historically been classified in two distinct genetic clades. The Central African (or Congo Basin) clade has been described to be more virulent with a case fatality ratio (CFR) ranging from 1-10% and the West African (WA) clade, less so, with a mortality of < 3%. The WA clade has been identified as the causal agent of the current outbreak3. Sporadic outbreaks have occurred outside of its ecological niche, including in the USA in 2003 and the UK in 20184, 5. Since May 13th 2022 a sharp increase in cases, predominantly in the USA and Europe, has brought widened attention to this neglected infectious disease. Concern has arisen due to a high rate of human-to-human transmission and there are current efforts to understand what is driving this transmission6. It is unclear what is driving the rising incidence of MPX; however, negligible global levels of immunity to the smallpox virus and its vaccine is a potential factor because smallpox immunity may provide protection against MPX infection7.

While dermatological manifestations in the form of a synchronous skin rash in patients with MPX are well documented and characterised, other sequelae such as possible neuropsychiatric effects MPX have yet to be systematically synthesised. Analogous data from smallpox infection and vaccination with Vaccinia (a related Orthopoxvirus) indicate that neurological and psychiatric features may be significant. Encephalopathy is a common feature of the clinical presentation of smallpox8 and, whilst rare, cases of encephalitis, seizures and stroke have been described following both smallpox infection and vaccination9, 10. Encephalitis is estimated to occur in 1 in 500 patients infected with the Variola major strain of smallpox and in 1 in 2,000 patients infected with the Variola minor strain, occurring 6-10 days after infection9. Post-vaccination encephalitis is estimated to occur at a rate of between 2 and 1,219 cases per 100,000 vaccines11 with higher rates thought to be associated with use of more neurotropic vaccinia strains10, providing prima facie support for the relevance of Orthopoxvirus biology in the aetiopathology of these sequelae.

In this systematic review and meta-analysis we aimed to (1) summarise the prevalences of neurological and psychiatric presentations of human MPX infection and (2) describe the spectrum of such presentations.

Methods

This systematic review and meta-analysis was pre-registered on PROSPERO (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=336649). It is reported according to PRISMA guidelines (checklist is included in Supplementary Table 1).

Eligibility criteria

Included study types were clinical trials, cohort studies, case-control studies, cross-sectional studies, case series or case reports. Due to the rapidly evolving nature of the literature, pre-prints were included. Studies had to report the prevalence of at least one neurological or psychiatric clinical feature. There were no exclusion criteria based on language. Included studies reported human participants of any age diagnosed with an MPX infection. In order to address our first question about prevalence, studies had to have a minimum of 10 subjects.

Searches

Ovid was used to search MEDLINE, EMBASE, PsycINFO and AMED without filters or limits up to 31/05/2022. The overall search strategy was to combine terms indicating MPX infection AND terms indicating neurological or psychiatric presentations. Text searches and subject headings were used. The full search strategy is presented in Supplementary Methods 1. MedRxiv was searched for pre-prints published in the previous 12 months. There was manual searching of the reference lists of included papers and other relevant systematic reviews to identify additional relevant studies. Authors in the field were contacted in an attempt to identify unpublished data.

Screening of titles and abstracts for each article was conducted independently by three of the authors (JB, IC, CJW) using Rayyan QCRI (http://www.rayyan.ai/). Where there was disagreement, articles were included for reviewing in the next stage. The list of potentially eligible full texts was imported to a spreadsheet, where two authors (JB, IC) independently assessed eligibility by comparing studies against the eligibility criteria. Where there was disagreement on the inclusion of a full text, a third author (JPR) arbitrated.

Data extraction

Two of the authors (JB, IC) independently extracted data from each study. Where relevant data were unclear or missing, study investigators were contacted by email for clarification. Where there were discrepancies between reviewers, the two reviewers discussed and agreed on a consensus.

Outcomes were defined as any neurological or psychiatric presentations in individuals infected with human MPX. Data were sought at the level of summary estimates. The specific neurological and psychiatric presentations on which data were collected were derived post hoc from the data available in the included papers. All results that were compatible with an outcome in each study were included. Data were also collected for the following study characteristics: study metadata (title, author, citation), country of study population, data collection period, study population, single- vs multicentre, study design, inclusion criteria, exclusion criteria, number with a suspected MPX infection, number in whom MPX infection was confirmed, method of MPX confirmation, number of cases not hospitalised, number of cases hospitalised, number of cases hospitalised and admitted to intensive care, number of cases female, age (mean, SD, median and IQR) of the cases, ethnicity of cases, whether there was a control group, number in the control group, control group description, control group matching parameters, method of identification of neurological or psychiatric presentations, temporality of neurological or psychiatric presentations, number with each available neurological or psychiatric presentation, investigation results, qualitative data, outcome and mortality.

Where an outcome was mentioned in at least one participant in a study, it was assumed that it was not present in any participants in whom it was not mentioned. Where relevant data were only available in graphical representations, e.g., Reynolds et al., manual graphical methods were used to estimate prevalence figures12.

Outcomes, summary measures, and synthesis of results

Results for each outcome were grouped together for analysis. The effect measures sought were period prevalences over the course of the illness. Studies were tabulated in two ways. In one table, each included study was presented sequentially, summarising its design, participants and outcomes. In a second table, results were presented grouped by neurological or psychiatric presentations.

Meta-analyses

For the meta-analysis, every neuropsychiatric presentation reported by two or more studies was examined. In certain instances there was evidence of overlapping populations between studies, potentially affecting prevalence estimates. To manage this, where overlap was suspected (e.g., Nigeria:13–16; USA;4, 17, 18 the study with the largest population was included in meta-analysis. However, if for a given presentation (e.g., myalgia or encephalitis) the study with the largest population did not report data for that symptom, the study with the next largest population was chosen for that particular symptom.

Results were pooled with random-effects meta-analysis, using the metafor package19 in R version 4.0.2 to calculate generalised linear mixed models for each prevalence outcome20, 21 before using the inverse variance method with the Freeman–Tukey double arcsine transformation as a comparative sensitivity analysis22. Between-study heterogeneity was assessed using the I² statistic. For interpretation, forest plots were produced with 95% confidence intervals (CIs). Subgroup analyses were planned to investigate heterogeneity where there were five or more included studies for any particular outcome by the following groups: study design (prospective vs retrospective), illness severity, method of diagnosis (serological vs clinical). The threshold for statistical significance was set to p-values of less than 0.05.

Risk of bias

Risk of bias was assessed using the Newcastle-Ottawa Scale for cohort studies, case-control studies and cross-sectional studies23. For case reports and case series, the Joanna Briggs Institute quality assessment tool was used24. Two authors assessed each study independently (JB, IC). Where there were discrepancies, a third author arbitrated (ER). Results for each study were presented and patterns in scores analysed. The overall certainty of the evidence was determined by a consideration of the heterogeneity and the risk of bias for an outcome.

Patient and public involvement

Due to the urgency of this review, patients and members of the public were not involved in the design of this study. The Encephalitis Society, the world’s largest brain inflammation charity, were consulted during the analysis and writing-up stage for assistance in interpretation of the results, and is reflected by Dr Easton’s co-author status.

Results

The search strategy yielded 2,285 studies. After automatic and manual de-duplication, the titles and abstracts of 1,702 studies were screened and the full texts of 85 studies were assessed for eligibility. An additional seven studies were included from screening references of eligible studies and other relevant systematic reviews. A total of 19 eligible studies were included (Figure 1 - Prisma). Brief reasons for excluding studies are listed in Table S1. Authors were contacted for unpublished data.

Figure 1:
Figure 1:

PRISMA flow diagram

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Population and study characteristics

The 19 studies included a total population n=1,512 individuals (sample size range 1-370; median n=21) with suspected MPX, n=1,031 (68.9%) of whom had infection confirmed by PCR. The mean (SD) age reported was 24.219.2) years, based on only 8 studies (n=542). Just under half of the population was female (n=465, 44.8%). Among studies reporting the setting of MPX treatment (12 studies, n=390), most patients were hospitalised (n=331, 84.9%). Ethnicity was explicitly reported in only three studies (n=54) in whom all were from the USA and 46 (85%) were White. Most studies originated in the USA (six studies) followed by Nigeria, the Democratic Republic of Congo (five studies each), the Republic of Congo (two studies), and the UK (one study) (Table 1).

View this table:
Table 1:

Characteristics of included subjects and studies

Most studies (12/19) had a cohort design, two were cross-sectional and the remainder were case series (four) and one case report. Only one study included a comparison group25. There was an equal split of prospective and retrospective cohort and cross-sectional studies.

Study quality scores were assessed using the Newcastle-Ottawa Scale (cohort and cross-sectional studies) and Joanna Briggs Quality Assessment Tool (case series and reports) are summarised in Table 2. Regarding the former, studies were generally scored down for no points on comparability due to a lack of control group in all bar one of the included studies. Furthermore, a lack of reported follow-up for the majority of studies also reduced the outcome score on the Newcastle Ottawa.

View this table:
Table 2:

Quality Assessment Scores

Study populations were mostly drawn from national case surveillance projects (e.g., Nigeria:15, 16.; USA:4, 17 or cohort studies evaluating the same outbreak of MPX18, 26, 27 Table 3. Other populations were more selective, including a sample of individuals co-infected with Varicella zoster virus25 or an evaluation of veterinary workers exposed to an infected prairie dog[28]. All studies confirmed MPX infection with PCR, except for Boumandouki et al29, and Centre for Disease Control (CDC) definitions of confirmed cases were followed in most studies. Nine studies reported the clade of MPX isolated in infected individuals. Of these, the majority were West African variants including all six studies in the USA. Two studies reported smallpox vaccination status29, 30 of which, the latter found deaths from MPX infection were confined to those not vaccinated for smallpox.

View this table:
Table 3

summary of included studies

Furthermore, mortality was reported in ten studies and varied between 0-25% in studies with 10 or more individuals. Neurological and psychiatric presentations varied widely, however, the most frequently reported were headache, myalgia, seizure, confusion, encephalitis and fatigue (table 3). Neuropsychiatric features were mostly evaluated through case note review in retrospective studies and a mix of clinical interview and questionnaire in prospective studies. The breadth of clinical features assessed in the latter design was minimal. For example, in two prospective studies, the only neuropsychiatric presentations evaluated were headache, fatigue and myalgia15; Croft et al28 headache only. Assessment of clinical feature severity, using standardised scales, and chronicity was also lacking.

Prevalence of neurological and psychiatric presentations

After exclusion of potentially overlapping populations, six neuropsychiatric presentations were eligible for meta-analysis of prevalence. The most frequent clinical feature was myalgia (pooled prevalence=55.5% [95%CI 12.1-91.9%]), followed by headache (53.8% [30.6-75.4%]), fatigue (36.2% [2.0-94.0%]), seizure (2.7% [0.6-10.2%]), confusion (2.4% [1.1-5.2%]) and encephalitis (2.0% [0.5-8.2%]) (Figure 2 – forest plots, Table 4 – prevalence of neurological and psychiatric presentations). Heterogeneity significantly varied across clinical features (I2=0%-98.7%, Table 4). Other neuropsychiatric presentations including dizziness, pain, altered vision, encephalopathy, photophobia, depression, anxiety and suicide are summarised in table 3.

View this table:
Table 4

Pooled prevalence of individual neurological and psychiatric presentations

Figure 2
Figure 2
Figure 2 Forest plots for individual neurological and psychiatric manifestations

Secondary analysis

There was no statistical evidence for a difference in the prevalence of headache in prospective compared to retrospective studies (based on four and two studies respectively – Figure 3 subgroup analysis of headache). It was not possible to analyse subgroups based on illness severity or method of diagnosis due to missing data and lack of variation between groups. No other clinical features met our prespecified eligibility criteria for subgroup analysis.

Discussion

This systematic review and meta-analysis provides the first comprehensive overview of the prevalence of neurological and psychiatric presentations of MPX infection. Based on a small number of studies examining this topic, headache and myalgia are present in over half of individuals and more severe central nervous system complications, including encephalitis and seizure, are present in small (<3%) but non-negligible proportions of infected individuals. The prevalence of other neuropsychiatric symptoms including fatigue, anxiety and depression are less clear. There are also knowledge gaps surrounding putative factors which influence risk of neurological and psychiatric presentations including overall MPX illness severity and viral clade.

The relatively high prevalence of non-specific symptoms such as headache and myalgia is perhaps unsurprising given that these symptoms are common in viral infections36–38. It is likely that these symptoms represent a reaction to systemic illness rather than direct neurological injury. Additionally, a paucity of follow-up and lack of evaluation of symptom severity and timing makes it hard to ascertain whether these symptoms are potentially highly disabling or milder and/or transient. These findings are consistent with a recently published review of MPX epidemiology which found that fatigue/asthenia and headache were present in over a fifth of individuals and myalgia in slightly fewer39. Although less frequently assessed, there was some evidence of psychiatric symptoms in people with MPX. For example, Ogoina and colleagues (2020)13 found that psychiatric manifestations including anxiety and depression were present in over a quarter of individuals hospitalised with MPX in Nigeria. Similarly, a case series from specialist centres in the UK found that three of seven patients admitted to hospital suffered from low mood5. Although severity data was not reported, in both studies individuals with psychiatric symptoms required inpatient psychological therapies. It is important to note that anxiety and depression are common in hospitalised patients, and indeed in those who are in quarantine for infectious diseases, and the majority of individuals in this review were drawn from quarantined hospitalised samples40, 41. This evidence could point to an underrecognized and understudied burden of psychiatric complications in the acute phase of MPX.

The quality of evidence included in this review may reflect the relatively understudied phenomena of nervous system presentations in the context of MPX and affects what conclusions can be drawn. Only one study included a control group, where individuals with Varicella zoster virus (VZV) and MPX were compared to those with MPX only and with VZV only25. Individuals with MPX and VZV co-infection were more likely to report fatigue than those with VZV alone, however, no comparative data were given for the MPX only group and no other neuropsychiatric symptoms of interest were compared. However, the clinical manifestations of VZV and MPX co-infection are complicated and the differences between individuals with co-infection and those with VZV alone may not be solely attributable to the effect of MPX. Attributing causality of viral infection to neurological symptoms is difficult despite established criteria used to define it42. This is exacerbated by a lack of adequate comparison groups, such as healthy controls or individuals with other viral illnesses. Additionally, incidence cannot be ascertained without reporting of premorbid neurological or psychiatric diagnoses. Small sample sizes also reduce the reliability of prevalence estimates.

Half of the included studies were retrospective and relied on case note review, which risks a systematic under-representation of symptoms, especially, if neuropsychiatric features were not routinely inquired about or assessed, although this is likely to be less of an issue with severe neurological complications. Additionally, no studies included in this review assessed psychiatric symptoms using standardised scales. The clinical significance of these symptoms is thus difficult to ascertain. In terms of data synthesis, we were limited by a lack of reporting of certain variables including MPX severity, ethnicity, and clade of MPX. The small number of studies means that subgroup analysis should be considered purely exploratory. Limited reporting of neurological investigations such as CSF analysis and neuroimaging also hinder understanding of the pathogenesis and potential mechanisms underlying the presentations described.

Though there has been little experimental work conducted on MPX and the nervous system in humans, a small number of case reports looking at smallpox have pointed to several diverse mechanistic explanations. Post-mortem examination revealed acute perivenular demyelination in patients known to have died of smallpox43. Additionally, MRI scans in those with post-vaccination encephalitis have been suggestive of acute disseminated encephalomyelitis (ADEM)10. However, to date CSF from patients with post-vaccine CNS complications has overwhelmingly been normal with no viral load detected, consistent with aseptic meningitis9, pointing to an immune-mediated pathogenesis. However, caution is required in extrapolating from either variola or vaccinia effects or neuropathology to MPX, despite shared genetics and clinical overlap between these Orthopoxviruses and their respective clinical syndromes. One case report included in this review of a child with MPX encephalitis, could not isolate viral material from CSF but did detect MPX specific IgM antibodies in CSF17, 26. This may suggest an intrathecal immune-mediated response; however, other cases of MPX-encephalitis did not report results of CSF analysis13. The underlying mechanisms of MPX neuropsychiatric manifestations include a direct CNS infection, an immune mediated response and a psychological reaction to illness.

Stigma could play a role in maladaptive psychological processes in those with MPX. Several studies emphasise the stigma associated with a diagnosis of MPX both on the individual, their family and integration back into society. Low mood was a common feature seen amongst many infected with MPX13. One patient died from suicide a few days after admission. The reports cited worries regarding how he had contracted MPX, and the effects on both him and his family13. Others highlight the stigma associated with the focus on transmission related to close physical contact and sexual contact, which may place an unwarranted and potentially harmful emphasis on the LGBTQ+ community. Contemporary public health and education should make clear that although there have been a high number of cases in men who have sex with men, and some cases of MPX with co-infection of HIV/AIDS15, MPX can also be spread via direct contact, clothing, and respiratory secretions, and that anyone can become infected. Nevertheless Bragazzi et al, 202239 point out the potential for exacerbation of stigma in already stigmatised communities.

Viral infections are known to have profound psychological effects on those affected, such as fear, loss, discrimination and stigma[44]. Though the clinical course varies amongst individuals, a common progression of dermatological change is persistent scarring. Ogoina, 202013 report that not only were skin lesions widespread, itchy and tender causing disfigurement, but that patients may also develop genital ulcers which were particularly distressing. Meta-analysis indicates a significant burden of persistent anxiety and depression in patients with facial scarring45. In addition, Rumsey and Harcourt46 highlight the wider negative consequences such as reduced self-esteem and loss of identity. Whilst the studies included in this review focus on acute psychological symptoms, the long-term psychological consequences of MPX infection are unknown.

Similarly, it is unclear what the long-term outcomes for patients with MPX encephalitis are, aside from one reported death30. Given that encephalitis, of infectious or autoimmune aetiology, results in considerable neurological and neuropsychiatric morbidity47, collecting longitudinal data on affected individuals with this rare complication should be a high priority moving forward. The long-term neurocognitive effects of MPX infection also remain elusive. Pittman and colleagues (2022)32 reported a case of confusion and lethargy still present at discharge. Given the range of neuropsychiatric effects that occur in a proportion of people after several viral illnesses48–50 it may be worthwhile ascertaining whether these symptoms persist in MPX.

This paper has research and therapeutic implications. The variability in detection and reporting of neuropsychiatric manifestations highlights the need for registries of emerging zoonotic infections where clinicians can provide case histories and reliable data in rapidly evolving epidemics such as the WHO clinical data platform51. The CoroNerve surveillance study52 demonstrates the utility of rapid reporting, having proved successful in the COVID-19 pandemic. Aside from epidemiology, there are therapeutic implications of this review. Our results suggest it would be worth researching the value of integrating psychological support into the care of those isolated with MPX both in the acute setting and beyond, including those managed in the community. The inclusion of encephalitis as well as the psycho-social and emotional impacts for patients of contracting MPX will likely have implications for patient quality of life and therefore increased research in this field is an important area yet to be adequately addressed for patients and their caregivers/families.

There is preliminary evidence for a range of neurological and psychiatric presentations of MPX, ranging from commonly reported and nonspecific neurological symptoms (myalgia and headache) to rarer but more severe neurological complications, such as encephalitis and seizures. There is less evidence regarding the psychiatric sequelae of MPX, and although there are multiple reports of anxiety and depression the prevalence of these symptoms is unknown. This preliminary suspicion that there are MPXV-related nervous system presentations may warrant surveillance within the current MPX outbreak, with prospective longitudinal studies evaluating the mid to long-term sequelae of the virus. well-powered prospective longitudinal studies to evaluate multi-system MPX effects. Robust methods to evaluate the potential causality of MPXV with these manifestations are required at an individual and epidemiological level.

Role of the Funding Source

MSZ, GL, ASD and CFH were supported by the NIHR University College London Hospitals Biomedical Research Centre. BDM is supported by the UKRI/MRC (MR/V03605X/1), the MRC-CSF (MR/V007181/1), the MRC/AMED (MR/T028750/1) and the Wellcome Trust (102186/B/13/Z). TAP is supported by an NIHR Clinical Lectureship. JPR is supported by the Wellcome Trust (102186/B/13/Z). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Competing Interests Statement

All authors have completed ICMJE uniform disclosure forms and declare; GL is supported by the UCLH BRC, is funded by NIHR, and is TSC chair for NIHR study. CW receives support from the Royal College of Psychiatrists Pathfinder Fellowship and the Association of British Neurologists’ Bursary. AE is a recipient of various grants for The Encephalitis Society which she is chief executive of, she has received payment for speaking and presentations from Pfizer, UCB, Bavarian Nordics, Valneva, CSL Behring and Biomerieux. MZ was supported to attend the European Academy of Neurology 2022 Encephalitis Workshop. No other relationships or activities that could appear to have influenced the submitted work.

Data Availability

The code created and used for the meta-analysis is available on GitHub (link included)

https://github.com/CameronWatson2020/monkeypox/blob/main/monkeypox_analysis.R

Supplementary material: PRISMA 2020 Checklist

View this table:

Supplementary material: PRISMA 2020 Checklist

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Supplementary methods: full search strategy

Medline

(Monkeypox OR monkeypox virus OR monkey pox OR MPV) AND ((neurol* OR nervous OR brain OR CNS OR encephal* OR mening* OR myeli* OR myalg* OR ADEM OR ataxi* OR dysphasi* OR aphasi* OR stroke OR guillain-barre OR Miller-Fisher OR paresis OR palsy OR cerebr* OR crani* OR epilep* OR seizure or headache* OR migraine* OR demyeli* OR neuroimag* OR neurotrop* OR neuroinvas* OR neuropath* OR cerebrospinal* or cerebro-spinal OR CSF OR*deliri* OR sleep OR insomnia OR somnolence OR hypersomnolence OR parasomnia OR "movement disorder" OR neuropsych* OR dement* OR cogniti* OR irritability OR hallucinat* OR delusion* OR apath* OR indifference OR agitat* OR euphori* OR elation OR elated OR disinhibit* OR aggressi* OR amnes* OR catatoni* OR personality OR psycho* OR mental OR mood OR affective OR depress* OR anxi* OR "obsessive compulsive" OR OCD OR "panic disorder" OR post-trauma* OR posttrauma* OR PTSD OR neurosis OR neurotic OR bipolar OR mania OR manic OR schizophreni* OR "intelligence quotient" OR IQ OR "mental retardation" OR "intellectual disability" OR "learning disability" OR autis* OR asperger* OR "attention deficit" OR ADHD OR hyperactivity OR hyperkinetic OR suicid* OR emotion* OR appetite OR fatigu* OR tired* OR confus*).ti,ab

OR

(exp Neurology/ or exp Nervous System/ or exp Nervous System Diseases/ or exp Neurologic Manifestations/ or exp Psychiatry/ or exp Mental Processes/ or exp Behavioral Symptoms/ or exp Psychological Phenomena/ or exp DELIRIUM/ OR exp SLEEP/ OR exp WAKEFULNESS/ OR exp SLEEP/ OR exp "DISORDERS OF EXCESSIVE SOMNOLENCE"/ OR exp PARASOMNIAS/ OR exp "PSYCHOMOTOR DISORDERS"/ OR exp DEMENTIA/ OR exp "NEUROCOGNITIVE DISORDERS"/ OR exp HALLUCINATIONS/ OR exp DELUSIONS/ OR exp APATHY/ OR exp "PSYCHOMOTOR AGITATION"/ OR exp EUPHORIA/ OR exp AGGRESSION/ OR exp AMNESIA/ OR exp CATATONIA/ OR exp "PERSONALITY DISORDERS"/ OR exp "SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS"/ OR exp "MENTAL DISORDERS"/ OR exp "MOOD DISORDERS"/ OR exp DEPRESSION/ OR exp ANXIETY/ OR exp "ANXIETY DISORDERS"/ OR exp "OBSESSIVECOMPULSIVE DISORDER"/ OR exp "PANIC DISORDER"/ OR exp "STRESS DISORDERS, POST-TRAUMATIC"/ OR exp "BIPOLAR AND RELATED DISORDERS"/ OR exp SCHIZOPHRENIA/ OR exp "INTELLECTUAL DISABILITY"/ OR exp "AUTISM SPECTRUM DISORDER"/ OR exp "ASPERGER SYNDROME"/ OR exp "ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS"/ OR exp "ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY"/ OR exp "MOTOR ACTIVITY"/ OR exp SUICIDE/ OR exp EMOTIONS/ OR exp APPETITE/ OR exp "FEEDING AND EATING DISORDERS"/ OR exp FATIGUE/ OR exp CONFUSION/)) [Humans]

Embase

(Monkeypox OR monkeypox virus OR monkey pox OR MPV) AND ((neurol* OR nervous OR brain OR CNS OR encephal* OR mening* OR myeli* OR myalg* OR ADEM OR ataxi* OR dysphasi* OR aphasi* OR stroke OR guillain-barre OR Miller-Fisher OR paresis OR palsy OR cerebr* OR crani* OR epilep* OR seizure or headache* OR migraine* OR demyeli* OR neuroimag* OR neurotrop* OR neuroinvas* OR neuropath* OR cerebrospinal* or cerebro-spinal OR CSF OR*deliri* OR sleep OR insomnia OR somnolence OR hypersomnolence OR parasomnia OR "movement disorder" OR neuropsych* OR dement* OR cogniti* OR irritability OR hallucinat* OR delusion* OR apath* OR indifference OR agitat* OR euphori* OR elation OR elated OR disinhibit* OR aggressi* OR amnes* OR catatoni* OR personality OR psycho* OR mental OR mood OR affective OR depress* OR anxi* OR "obsessive compulsive" OR OCD OR "panic disorder" OR post-trauma* OR posttrauma* OR PTSD OR neurosis OR neurotic OR bipolar OR mania OR manic OR schizophreni* OR "intelligence quotient" OR IQ OR "mental retardation" OR "intellectual disability" OR "learning disability" OR autis* OR asperger* OR "attention deficit" OR ADHD OR hyperactivity OR hyperkinetic OR suicid* OR emotion* OR appetite OR fatigu* OR tired* OR confus*).ti,ab

OR

(exp Neuroscience/ or exp Nervous System/ or exp Neurologic Disease/ or exp Psychiatry/ or exp Behavior/ or exp Mental Function/ or exp Psychophysiology/ or exp DELIRIUM/ OR exp "SLEEP DISORDER"/ OR exp INSOMNIA/ OR exp SOMNOLENCE/ OR exp HYPERSOMNIA/ OR exp PARASOMNIA/ OR exp "MOTOR DYSFUNCTION"/ OR exp DEMENTIA/ OR exp "COGNITIVE DEFECT"/ OR exp IRRITABILITY/ OR exp HALLUCINATION/ OR exp DELUSION/ OR exp APATHY/ OR exp AGITATION/ OR exp EUPHORIA/ OR exp AGGRESSION/ OR exp AMNESIA/ OR exp CATATONIA/ OR exp "PERSONALITY DISORDER"/ OR exp PSYCHOSIS/ OR exp "MENTAL DISEASE"/ OR exp MOOD/ OR exp "MOOD DISORDER"/ OR exp DEPRESSION/ OR exp 7 ANXIETY/ OR exp "ANXIETY DISORDER"/ OR exp "OBSESSIVE COMPULSIVE DISORDER"/ OR exp PANIC/ OR exp "POSTTRAUMATIC STRESS DISORDER"/ OR exp NEUROSIS/ OR exp "BIPOLAR DISORDER"/ OR exp MANIA/ OR exp PSYCHOSIS/ OR exp "SCHIZOPHRENIA SPECTRUM DISORDER"/ OR exp SCHIZOPHRENIA/ OR exp "INTELLIGENCE QUOTIENT"/ OR exp "MENTAL DISEASE"/ OR exp "INTELLECTUAL IMPAIRMENT"/ OR exp "DISORDERS OF HIGHER CEREBRAL FUNCTION"/ OR exp "LEARNING DISORDER"/ OR exp AUTISM/ OR exp "ATTENTION DEFICIT DISORDER"/ OR exp HYPERACTIVITY/ OR exp "PSYCHOMOTOR DISORDER"/ OR exp HYPERKINESIA/ OR exp SUICIDE/ OR exp "SUICIDAL BEHAVIOR"/ OR exp "SUICIDE ATTEMPT"/ OR exp EMOTION/ OR exp APPETITE/ OR exp "APPETITE DISORDER"/ OR exp FATIGUE/ OR exp CONFUSION))

[Humans]

Psychinfo

(Monkeypox OR monkeypox virus OR monkey pox OR MPV)

AND

((neurol* OR nervous OR brain OR CNS OR encephal* OR mening* OR myeli* OR myalg* OR ADEM OR ataxi* OR dysphasi* OR aphasi* OR stroke OR guillain-barre OR Miller-Fisher OR paresis OR palsy OR cerebr* OR crani* OR epilep* OR seizure or headache* OR migraine* OR demyeli* OR neuroimag* OR neurotrop* OR neuroinvas* OR neuropath* OR cerebrospinal* or cerebro-spinal OR CSF OR*deliri* OR sleep OR insomnia OR somnolence OR hypersomnolence OR parasomnia OR "movement disorder" OR neuropsych* OR dement* OR cogniti* OR irritability OR hallucinat* OR delusion* OR apath* OR indifference OR agitat* OR euphori* OR elation OR elated OR disinhibit* OR aggressi* OR amnes* OR catatoni* OR personality OR psycho* OR mental OR mood OR affective OR depress* OR anxi* OR "obsessive compulsive" OR OCD OR "panic disorder" OR post-trauma* OR posttrauma* OR PTSD OR neurosis OR neurotic OR bipolar OR mania OR manic OR schizophreni* OR "intelligence quotient" OR IQ OR "mental retardation" OR "intellectual disability" OR "learning disability" OR autis* OR asperger* OR "attention deficit" OR ADHD OR hyperactivity OR hyperkinetic OR suicid* OR emotion* OR appetite OR fatigu* OR tired* OR confus*).ti,ab OR (exp Psychiatry/ OR exp Sensory System Disorders/ OR exp Sense Organ Disorders/ OR exp Nervous System Disorders/ OR exp Neurosciences/ or exp Emotional States/ OR exp DELIRIUM/ OR exp "NEUROCOGNITIVE DISORDERS"/ OR exp "SLEEP WAKE DISORDERS"/ OR exp INSOMNIA/ OR exp HYPERSOMNIA/ OR exp "MOVEMENT DISORDERS"/ OR exp DEMENTIA/ OR exp "COGNITIVE ABILITY"/ OR exp "COGNITIVE IMPAIRMENT"/ OR exp "NEUROCOGNITIVE DISORDERS"/ OR exp IRRITABILITY/ OR exp HALLUCINATIONS/ OR exp DELUSIONS/ OR exp APATHY/ OR exp AGITATION/ OR exp EUPHORIA/ OR exp "BEHAVIORAL DISINHIBITION"/ OR exp AMNESIA/ OR exp CATATONIA/ OR exp PERSONALITY/ OR exp "PERSONALITY DISORDERS"/ OR exp PSYCHOSIS/ OR exp "MENTAL DISORDERS"/ OR exp EMOTIONS/ OR exp "AFFECTIVE DISORDERS"/ OR exp "DEPRESSION (EMOTION)"/ OR exp ANXIETY/ OR exp "ANXIETY DISORDERS"/ OR exp "OBSESSIVE COMPULSIVE DISORDER"/ OR exp "PANIC DISORDER"/ OR exp "POSTTRAUMATIC STRESS"/ OR exp NEUROSIS/ OR exp "BIPOLAR DISORDER"/ OR exp MANIA/ OR exp SCHIZOPHRENIA/ OR exp "INTELLIGENCE QUOTIENT"/ OR exp "NEURODEVELOPMENTAL DISORDERS"/ OR exp "INTELLECTUAL DEVELOPMENT DISORDER"/ OR exp "AUTISM SPECTRUM DISORDERS"/ OR exp "ATTENTION DEFICIT DISORDER"/ OR exp HYPERKINESIS/ OR exp SUICIDE/ OR exp EMOTIONS/ OR exp APPETITE/ OR exp "EATING DISORDERS"/ OR exp FATIGUE/ OR exp "MENTAL CONFUSION"/)

[Population Human]

MedRxiv

(Monkeypox OR monkeypox OR monkey pox OR MPV)

In categories psychiatry and clinical psychology; neurology

Footnotes

  • ↵* Joint first authors

  • ↵⍰ Joint last authors

  • jamiebadenoch{at}gmail.com, iconti02{at}qub.ac.uk, emmarachelrengasamy{at}gmail.com, cameron.watson{at}qmul.ac.uk, matthew.butler{at}kcl.ac.uk, zhuss95{at}gmail.com, Ally.Rooney{at}ed.ac.uk, Benedict.Michael{at}liverpool.ac.uk, m.zandi{at}ucl.ac.uk, glyn.lewis{at}ucl.ac.uk, anthony.s.david{at}ucl.ac.uk, c.houlihan{at}ucl.ac.uk, ava{at}encephalitis.info, kuppallik{at}who.int, timothy.nicholson{at}kcl.ac.uk, thomas.pollak{at}kcl.ac.uk, jonathan.rogers{at}ucl.ac.uk

  • Author's name typo

References

  1. 1.↵
    Centres for Disease Control and Prevention. (2022)[accessed 21 June 2022] https://www.cdc.gov/poxvirus/monkeypox/index.html
  2. 2.↵
    Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication 1988. World Health Organization, History of International Public Health, No. 6 https://apps.who.int/iris/handle/10665/39485
  3. 3.↵
    Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl Trop Dis 2022, 16(2). https://doi.org/10.1371/journal.pntd.0010141
  4. 4.↵
    Huhn GD, Bauer AM., Yorita K, Graham MB, Sejvar J, Likos A, et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 2005, 41(12):1742–51. https://doi.org/10.1086/498115
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan C, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022, S1473-3099(22)00228-6. doi:10.1016/S1473-3099(22)00228-6
    OpenUrlCrossRef
  6. 6.↵
    Dye C, Kraemer MUG. Investigating the monkeypox outbreak. BMJ 2022 May 26;377:o1314. https://doi.org/10.1136/bmj.o1314
    OpenUrlFREE Full Text
  7. 7.↵
    Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA 2010, 107(37):16262–7. doi:10.1073/pnas.1005769107
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002, 346(17):1300–8. doi:10.1056/NEJMra020025
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Han MH, Zunt JR. Bioterrorism and the nervous system. Curr Neurol Neurosci Rep 2003, 3:476–82. doi:10.1007/s11910-003-0050-9
    OpenUrlCrossRefPubMed
  10. 10.↵
    Sejvar J, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM. Neurological adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 2005, 294(21):2744–49. doi:10.1001/jama.294.21.2744
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Cleri DJ, Villota FJ, Porwancher RB. Smallpox, bioterrorism, and the neurologist. Arch Neurol 2003, 60:489–94. doi:10.1001/archneur.60.4.489
    OpenUrlCrossRefPubMed
  12. 12.↵
    Van der Mierden S, Spineli LM, Talbot SR, Yinnakou C, Zentrich E, Weegh N, et al. Extracting data from graphs: A case-study on animal research with implications for meta-analyses. Res Synth Methods 2021,12(6):701-710. doi:10.1002/jrsm.1481. Epub 2021 Feb 19.
    OpenUrlCrossRef
  13. 13.↵
    Ogoina D, Iroezindu M, Izibewule JH, Oladokun R, Yinka-Ogunleye A, Wakama P, et al. Clinical course and outcomes of human monkeypox in Nigeria. Clin Infect Dis 2020, 71(8):e210–14. https://doi.org/10.1093/cid/ciaa143
    OpenUrl
  14. 14.
    Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, et al. The 2017 human monkeypox outbreak in Nigeria—Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PLoS ONE 2019, 14(4): e0214229. https://doi.org/10.1371/journal.pone.0214229
    OpenUrlCrossRef
  15. 15.↵
    Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis 2019, 19(8), 872–879. doi:10.1016/S1473-3099(19)30294-4
    OpenUrlCrossRefPubMed
  16. 16.↵
    Akar S, Adesola YO, Akar S, Burga J, Oluwafemi B, Akinrogbe J, et al. Descriptive epidemiology of monkeypox in Nigera, September 2017 -June 2019. Int J Infect Dis 2020, in press https://doi.org/10.1016/j.ijid.2020.11.012
  17. 17.↵
    Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner WM, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004, 350(4), 342–350. doi:10.1056/NEJMoa032299
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holan RC, et al. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis 2006, 194(6):773–780. https://doi.org/10.1086/505880
    OpenUrlCrossRefPubMed
  19. 19.↵
    Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw 2010, 36:1–48. https://doi.org/10.18637/jss.v036.i03
    OpenUrlCrossRefPubMed
  20. 20.↵
    Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008;61:41–51. doi:10.1016/j.jclinepi.2007.03.016
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 2010, 29:3046–3067. https://doi.org/10.1002/sim.4040
    OpenUrlCrossRefPubMed
  22. 22.↵
    Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat 1950, 21:607–611. doi:10.1214/aoms/1177729756
    OpenUrlCrossRef
  23. 23.↵
    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. [Accessed 20.6.22] http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  24. 24.↵
    The Joanna Briggs Institute. The Joanna Briggs institute critical appraisal tools for use in JBI systematic reviews: checklist for case series. 2017. [accessed 23 June, 2022]. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Case_Series2017_0.pdf
  25. 25.↵
    Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe B, et al. A tale of two viruses: coinfections of monkeypox and varicella zoster virus in the Democratic Republic of Congo. Am J Trop Med Hyg 2021, 104(2):604–11. doi:10.4269/ajtmh.20-0589
    OpenUrlCrossRef
  26. 26.↵
    Sejvar JJ, Chowdary Y, Schomogyi M, Stevens J, Patel J, Karem K, et al. Human Monkeypox Infection: A Family Cluster in the Midwestern United States. J Infect Dis 2004, 190(10):1833–1840. https://doi-org.ezp.lib.cam.ac.uk/10.1086/425039
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    Anderson MG, Frenkel LD, Homann S, Guffey J. A case of severe monkeypox virus disease in an American child: emerging infections and changing professional values. Pediatr Infect Dis J 2003, 22(12):1093–96. doi:10.1097/01.inf.0000101821.61387.a5
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    Croft DR, Sotir MJ, Williams CJ, Kazmierczak JJ, Wegner MV, Rausch D, et al. Occupational risks during a monkeypox outbreak, Wisconsin, 2003. Emerg Infect Dis 2007, 13(8):1150-57. doi:10.3201/eid1308.061365
    OpenUrlCrossRefPubMed
  29. 29.↵
    Boumandouki P, Bileckot R, Ibara JR, Satounkazi C, Wassa Wassa D, Libama E, et al. Simian smallpox (or monkey smallpox): study of 8 cases observed at Impfondo Hospital in Republic of Congo. Bull Soc Pathol Exot 2007, 100(1):17–21
    OpenUrl
  30. 30.↵
    Ježek Z, Szczeniwoski M, Paluku KM, Mutombo M. Human Monkeypox: Clinical Features of 282 Patients. J Infect Dis 1987, 156(2)293–298, https://doi-org.ezp.lib.cam.ac.uk/10.1093/infdis/156.2.293
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.
    Eseigbe EE, Akude C, Osagie IA, Eseigbe P. Human monkey pox virus infection in Pleateau State, north central Nigeria: a report of two cases. West Afr J Med 2021, 38(12):1242–46.
    OpenUrl
  32. 32.↵
    [preprint] Pittman PR, Martin JW, Kingebeni PM, Tamfum JM, Wan Q, Reynolds MG, et al. Clinical characterization of human monkeypox infections in the Democratic Republic of the Congo. medRxiv [accessed 23 June, 2022]
  33. 33.
    Kalthan E, Dondo-Fongbia JP, Yambele S, Dieu-Creer LR, Zepio R, Pamatika CM. Epidémie de 12 cas de maladie à virus monkeypox dans le distric de Bangassou en République Centrafricaine en décembre 2015. Bull Soc Pathol Exot 2016, 109(1):358–63. doi:10.1007/s13149-016-0516-z
    OpenUrlCrossRef
  34. 34.
    Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 2005, 73(2):428-35. https://doi.org/10.4269/ajtmh.2005.73.428
    OpenUrlAbstract/FREE Full Text
  35. 35.
    Reynolds MG, Emerson GL, Pukuta E, Karhemere S, Muyembe JJ, Bikindou A, et al. Short report: Detection of human monkeypox in the Republic of Congo following intensive community education. Am J Trop Med Hyg 2013;88(5):982–85. doi:10.4269/ajtmh.12-0758
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. Front Cell Neurosci 2018,12:386. doi: 10.3389/fncel.2018.00386
    OpenUrlCrossRefPubMed
  37. 37.
    Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RTR, Werno AM, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008, 63(1):42–8. doi: 10.1136/thx.2006.075077. Epub 2007 Jun 15
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020, 7(7):611–627. doi:10.1016/S2215-0366(20)30203-0.
    OpenUrlCrossRefPubMed
  39. 39.↵
    Bragazzi NL, Khamisy-Farah R, Tsigalou C, Mahroum N, Converti M. Attaching a stigma to the LGBTQI+ community should be avoided during the monkeypox epidemic. J Med Virol 2022. doi: 10.1002/jmv.27913. Epub ahead of print.
    OpenUrlCrossRef
  40. 40.↵
    Walker J, Burke K, Wanat M, Fisher R, Fielding J, Mulick A, et al. The prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studies. Psychol Med 2018;48(14):2285–98. doi:10.1017/S0033291718000624
    OpenUrlCrossRefPubMed
  41. 41.↵
    Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 2020;395(10227):912–920. doi: 10.1016/S0140-6736(20)30460-8
    OpenUrlCrossRefPubMed
  42. 42.↵
    Ellul M, Varatharaj A, Nicholson TR, Pollak TA, Thomas N, Easton A, et al. Defining causality in COVID-19 and neurological disorders. J Neurol Neurosurg Psychiatry 2020;91(8):811–812. doi: 10.1136/jnnp-2020-323667.
    OpenUrlFREE Full Text
  43. 43.↵
    Marsden JP. Acute perivascular myelinoclasis “acute disseminated encephalomyelitis”: a report of two further cases associated with exanthemata. Lancet 1934, 224:871–2.
    OpenUrl
  44. 44.
    Pappas G, Kiriaze IJ, Giannakis P, Falgas ME. Psychosocial consequences of infectious diseases. Clin Microbiol Infect 2009, 15(8), 743–747. doi:10.1111/j.1469-0691.2009.02947.x
    OpenUrlCrossRefPubMed
  45. 45.↵
    Gibson JA, Ackling E, Bisson JI, Dobbs TD, Whitaker ISl. The association of affective disorders and facial scarring: Systematic review and meta-analysis. J Affect Disord 2018, 239, 1–10. doi:10.1016/j.jad.2018.06.013
    OpenUrlCrossRef
  46. 46.↵
    Rumsey N, Harcourt D. Body image and disfigurement: issues and interventions. Body image 2004, 1(1), 83–97. doi:10.1016/S1740-1445(03)00005-6
    OpenUrlCrossRefPubMed
  47. 47.↵
    Bohmwald K, Andrade CA, Gálvez NMS, Mora VP, Muñoz JT, Kalgeris AM. The causes and long-term consequences of viral encephalitis. Front Cell Neruosci 2021, 15(1):755875. doi:10.3389/fncel.2021.755875
    OpenUrlCrossRef
  48. 48.↵
    Dubé B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005, 30(4):237–46. Erratum in: J Psychiatry Neurosci 2005, 30(5):365
    OpenUrl
  49. 49.
    Manjunatha N, Math SB, Kulkarni GB, Chaturvedi SK. The neuropsychiatric aspects of influenza/swine flu: A selective review. Ind Psychiatry J 2011, 20:83–90. doi: 10.4103/0972-6748.102479
    OpenUrlCrossRef
  50. 50.↵
    Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Comms 2020, 4(1):fcab297 https://doi.org/10.1093/braincomms/fcab297
    OpenUrl
  51. 51.↵
    World Health Organisation. Clinical management and infection prevention and control for monkeypox: Interim rapid response guidance. 2022. https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1 [accessed 24 June 2022]
  52. 52.↵
    Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020, 7(10):875–882 doi:10.1016/S2215-0366(20)30287-X
    OpenUrlCrossRefPubMed
Back to top
Posted July 11, 2022.
Download PDF
Data/Code
Email
Neurological and psychiatric presentations associated with human monkeypox virus infection: a systematic review and meta-analysis
James B Badenoch, Isabella Conti, Emma R Rengasamy, Cameron J Watson, Matthew Butler, Zain Hussain, Alasdair G Rooney, Michael S Zandi, Glyn Lewis, Anthony S David, Catherine F Houlihan, Ava Easton, Benedict D Michael, Krutika Kuppalli, Timothy R Nicholson, Thomas A Pollak, Jonathan P Rogers
medRxiv 2022.07.03.22277069; doi: https://doi.org/10.1101/2022.07.03.22277069
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area